Global biotech giant Roche has announced that the U.S. Food and Drug Administration (FDA) has awarded its candidate Alzheimer's Disease drug gantenerumab Breakthrough Therapy Designation, bringing it closer to finally getting a full FDA approval.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,